Total Payments
$4,626
2024 Payments
$1,084
Companies
39
Transactions
201
Medicare Patients
1,609
Medicare Billing
$331,335
Payment Breakdown by Category
Food & Beverage$4,330 (93.6%)
Education$296.93 (6.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,330 | 197 | 93.6% |
| Education | $296.93 | 4 | 6.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $589.66 | 26 | $0 (2024) |
| Myriad Genetic Laboratories, Inc. | $376.07 | 9 | $0 (2024) |
| Gilead Sciences, Inc. | $309.15 | 8 | $0 (2024) |
| Janssen Biotech, Inc. | $294.53 | 14 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $274.57 | 16 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $247.94 | 13 | $0 (2024) |
| Merck Sharp & Dohme LLC | $213.49 | 11 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $193.68 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $192.69 | 8 | $0 (2024) |
| Celgene Corporation | $168.37 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,084 | 50 | Novartis Pharmaceuticals Corporation ($216.90) |
| 2023 | $2,852 | 121 | Myriad Genetic Laboratories, Inc. ($359.14) |
| 2022 | $675.65 | 29 | EISAI INC. ($125.00) |
| 2017 | $14.52 | 1 | E.R. Squibb & Sons, L.L.C. ($14.52) |
All Payment Transactions
201 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Education | Cash or cash equivalent | $34.95 | General |
| Category: Oncology | ||||||
| 09/09/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $31.25 | General |
| Category: Immunology | ||||||
| 06/21/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: Oncology | ||||||
| 06/17/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $33.10 | General |
| Category: Immunology | ||||||
| 06/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: ONCOLOGY | ||||||
| 06/07/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $13.36 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 06/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $21.31 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 05/30/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $21.69 | General |
| Category: Hematology | ||||||
| 05/24/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Oncology | ||||||
| 05/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.05 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $32.40 | General |
| Category: Immunology | ||||||
| 05/16/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 05/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: Oncology | ||||||
| 05/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.25 | General |
| Category: Oncology | ||||||
| 04/30/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $28.85 | General |
| Category: Iron Deficiency Anemia | ||||||
| 04/30/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $31.23 | General |
| Category: Oncology | ||||||
| 04/23/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $20.82 | General |
| 04/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: Oncology | ||||||
| 04/19/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 04/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.25 | General |
| Category: Oncology | ||||||
| 04/09/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $33.29 | General |
| Category: Oncology | ||||||
| 04/04/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $14.88 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 666 | 32,890 | $453,286 | $204,877 |
| 2022 | 9 | 225 | 319 | $79,827 | $30,062 |
| 2021 | 7 | 271 | 490 | $119,203 | $39,615 |
| 2020 | 6 | 447 | 1,063 | $212,318 | $56,782 |
Total Patients
1,609
Total Services
34,762
Medicare Billing
$331,335
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 12 | 1,910 | $127,970 | $68,113 | 53.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 148 | 310 | $62,500 | $31,335 | 50.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 1,620 | $51,360 | $29,829 | 58.1% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 19 | 24,750 | $49,500 | $21,795 | 44.0% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 22 | 2,290 | $34,350 | $12,847 | 37.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 23 | 58 | $27,724 | $6,518 | 23.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 57 | 104 | $23,400 | $5,771 | 24.7% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 16 | 750 | $9,000 | $4,647 | 51.6% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 12 | 62 | $4,340 | $4,430 | 102.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $8,845 | $4,009 | 45.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 104 | 311 | $19,593 | $3,672 | 18.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 23 | $8,165 | $3,295 | 40.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 19 | $5,134 | $2,656 | 51.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 23 | $3,128 | $1,518 | 48.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 20 | 55 | $5,500 | $1,364 | 24.8% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 18 | 64 | $4,480 | $1,120 | 25.0% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 20 | 32 | $3,840 | $665.10 | 17.3% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 18 | 30 | $1,350 | $555.80 | 41.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 13 | 29 | $1,711 | $384.77 | 22.5% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 17 | 23 | $1,035 | $251.84 | 24.3% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 17 | 35 | $105.00 | $39.63 | 37.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 12 | 322 | $161.00 | $31.54 | 19.6% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 12 | 28 | $82.00 | $21.82 | 26.6% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 11 | 13 | $13.00 | $6.61 | 50.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 47 | 47 | $19,600 | $8,421 | 43.0% |
About Lois Kamugisha
Lois Kamugisha is a Medical Oncology healthcare provider based in Northampton, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/12/2008. The National Provider Identifier (NPI) number assigned to this provider is 1134396948.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Lois Kamugisha has received a total of $4,626 in payments from pharmaceutical and medical device companies, with $1,084 received in 2024. These payments were reported across 201 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($4,330).
As a Medicare-enrolled provider, Kamugisha has provided services to 1,609 Medicare beneficiaries, totaling 34,762 services with total Medicare billing of $331,335. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology, Hematology
- Location Northampton, MA
- Active Since 05/12/2008
- Last Updated 08/01/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1134396948
Products in Payments
- MYRISK (Device) $376.07
- Rezlidhia (Drug) $225.79
- KEYTRUDA (Biological) $213.49
- OPDIVO (Biological) $201.79
- Trodelvy (Drug) $200.81
- ZEPZELCA (Drug) $193.68
- IMBRUVICA (Drug) $146.58
- KISQALI (Drug) $125.47
- Lenvima (Drug) $125.00
- Fabhalta (Drug) $113.97
- KRAZATI (Drug) $112.36
- DARZALEX (Biological) $111.50
- PROMACTA (Drug) $109.30
- Pomalyst (Drug) $102.95
- CABOMETYX (Drug) $99.16
- SCEMBLIX (Drug) $84.86
- Stivarga (Drug) $84.13
- SARCLISA (Biological) $71.41
- JAKAFI (Drug) $70.79
- IMFINZI (Biological) $70.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.